Finam

Category

Finam




Useful info

Finam Brand names, Finam Analogs

Finam Brand Names Mixture

  • Adderall (amphetamine + dextroamphetamine)
  • Adderall XR 10mg (Amphetamine Aspartate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate)
  • Adderall XR 15mg (Amphetamine Aspartate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate)
  • Adderall XR 20mg (Amphetamine Aspartate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate)
  • Adderall XR 25mg (Amphetamine Aspartate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate)
  • Adderall XR 30mg (Amphetamine Aspartate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate)
  • Adderall XR 5mg (Amphetamine Aspartate + Amphetamine Sulfate + Dextroamphetamine Saccharate + Dextroamphetamine Sulfate)

    • Finam Chemical_Formula

    C9H13N

    Finam RX_link

    http://www.rxlist.com/cgi/generic3/adderallxr.htm

    Finam fda sheet

    Finam msds (material safety sheet)

    Finam Synthesis Reference

    U. S. Pat. 1,879,003, (1932)

    Finam Molecular Weight

    135.206 g/mol

    Finam Melting Point

    Volatizes slowly at room temperature

    Finam H2O Solubility

    Slightly

    Finam State

    Solid

    Finam LogP

    1.799

    Finam Dosage Forms

    Capsules

    Finam Indication

    For treatment of Attention Deficit Disorder with Hyperactivity (ADDH) and narcolepsy in children.

    Finam Pharmacology

    Amphetamine and dextroamphetamine, non-catechloamine sypathomimetic agents, are used in combination to treat attention-deficit hyperactivity disorder (ADHD) or narcolepsy. Adderall consists of equivalent amounts of amphetamine aspartate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate.

    Finam Absorption

    It forms easily absorbed molecules that are highly lipid soluble

    Finam Toxicity

    LD50=180 mg/kg(s.c in rat). The most common presenting symptoms seen are agitation, hallucinations, suicidal behaviour, and chest pain.

    Finam Patient Information

    Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.

    Finam Organisms Affected

    Humans and other mammals